Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.

BiomedicineChina Future Tech /

Biomedicine

Related Topics:
Companies
Policy
Science
Industry Trends
Geopolitics
Illustration: Henry Wong
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Banking & finance

From chips to noodles: the newcomers testing Hong Kong’s buoyant IPO market

Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Shanghai

China bets on bio-manufacturing as new growth engine, bid for tech self-reliance

The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.

Biotech manufacturing has been identified as one of the key economic growth drivers in China’s 15th five-year plan. Photo: Shutterstock
Biotech manufacturing has been identified as one of the key economic growth drivers in China’s 15th five-year plan. Photo: Shutterstock
Banking & finance

3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO

As 3SBio lines up a Hong Kong spin-off for its hair-loss unit Mandi, the subsidiary is preparing a drug pipeline aimed at acne and obesity.

Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

Advertisement
Advertisement
Advertisement
Made in China 2025

‘Significant gains’: US review evaluates ‘Made in China 2025’ advancements

The decade-long strategy reduces strategic vulnerabilities and strengthens geopolitical leverage, congressional report finds.

videocam
17
Made in China 2025 was launched in 2015, a decade-long strategy to develop and incorporate advanced technologies into the manufacturing sector. Photo: SCMPOST
Made in China 2025 was launched in 2015, a decade-long strategy to develop and incorporate advanced technologies into the manufacturing sector. Photo: SCMPOST
IPO

Chinese drug developer Biokin postpones Hong Kong listing

Decision likely reflects ‘some pullback in risk appetite, with growth-stock share prices coming off their highs’, Morningstar analyst says.

China manufacturing

China’s southwestern industrial base eyes breakthroughs on novel drugs

As country pushes for scientific and technological self-reliance, Chongqing will provide support for pharmaceutical research and development.

China manufacturing

China’s ‘smart healthcare’ firms draw crowds as Canton Fair wraps up

While Chinese medical technology companies are gaining market share, insiders said trust still needs to be built for global success.

videocam
The “Intelligent Healthcare” zone, a new addition to the Canton Fair, has drawn attention from overseas buyers. Photo: Xinhua
Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

A facility manufacturing cancer drugs in Guangzhou. Photo: Handout
A facility manufacturing cancer drugs in Guangzhou. Photo: Handout
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Biomedicine: Companies

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

HKEX

HKEX’s new Hang Seng Biotech Index Futures to debut next month

The futures contracts platform aims to meet offshore investors’ heightened interest in Hong Kong-listed Chinese biopharmaceutical stocks.

The Hang Seng Biotech Index Futures will track the performance of the 30 largest Hong Kong-listed Chinese pharmaceutical and medical device companies. Photo: Shutterstock
Biomedicine: Companies

Mirxes wins China’s approval to launch groundbreaking gastric cancer blood test

The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally.

GastroClear, the first microRNA blood test approved in China for the early detection of gastric cancer, evaluates risks by detecting 12 miRNA biomarkers, according to developer Mirxes. Photo: Handout
GastroClear, the first microRNA blood test approved in China for the early detection of gastric cancer, evaluates risks by detecting 12 miRNA biomarkers, according to developer Mirxes. Photo: Handout
Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Advertisement
Advertisement
Advertisement
IPO

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.

The Hang Seng Biotech index, which tracks the 50 largest biotech, pharmaceutical and medical-device firms listed in Hong Kong, has surged 109 per cent this year. Photo: Shutterstock
The Hang Seng Biotech index, which tracks the 50 largest biotech, pharmaceutical and medical-device firms listed in Hong Kong, has surged 109 per cent this year. Photo: Shutterstock
Baidu

Baidu-backed drug discovery start-up Biomap challenges Google’s AlphaFold

Biomap expects to double its revenue this year, co-founder and CEO Wei Liu says.

Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Biomedicine: Companies

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

A worker checks a machine at Hengrui Biomedical Industrial Park in Lianyungang, in East China’s Jiangsu province, on December 13, 2021. Photo: Future Publishing via Getty Images
A worker checks a machine at Hengrui Biomedical Industrial Park in Lianyungang, in East China’s Jiangsu province, on December 13, 2021. Photo: Future Publishing via Getty Images
Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

US-China tech war

Chinese 3D biomolecule imaging start-up aims for IPO in 2027

Shuimu BioSciences is the first Chinese company to develop its own cryo-electron microscopy machine, a vital tool in drug discovery.

Allen Guo Chunlong, co-founder and CEO Shuimu BioSciences. Photo: Handout
Help preserve 120 years of quality journalism.
SUPPORT NOW